|
US4965188A
(en)
*
|
1986-08-22 |
1990-10-23 |
Cetus Corporation |
Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
|
|
US5130238A
(en)
*
|
1988-06-24 |
1992-07-14 |
Cangene Corporation |
Enhanced nucleic acid amplification process
|
|
US5364866A
(en)
*
|
1989-05-19 |
1994-11-15 |
Hoechst-Roussel Pharmaceuticals, Inc. |
Heteroarylpiperidines, pyrrolidines and piperazines and their use as antipsychotics and analetics
|
|
GB9001181D0
(en)
*
|
1990-01-18 |
1990-03-21 |
Imp Cancer Res Tech |
Genetic assay
|
|
US5846717A
(en)
*
|
1996-01-24 |
1998-12-08 |
Third Wave Technologies, Inc. |
Detection of nucleic acid sequences by invader-directed cleavage
|
|
JP2002539450A
(ja)
|
1999-03-15 |
2002-11-19 |
レイランド−ジョーンズ，ブライアン |
代謝表現型決定のためのｅｌｉｓａキット
|
|
AP2001002290A0
(en)
*
|
1999-04-07 |
2001-12-31 |
Pfizer Prod Inc |
Use of CYP2D6 inhibitors in combination therapies.
|
|
US20010034023A1
(en)
*
|
1999-04-26 |
2001-10-25 |
Stanton Vincent P. |
Gene sequence variations with utility in determining the treatment of disease, in genes relating to drug processing
|
|
US6960439B2
(en)
*
|
1999-06-28 |
2005-11-01 |
Source Precision Medicine, Inc. |
Identification, monitoring and treatment of disease and characterization of biological condition using gene expression profiles
|
|
US7250252B2
(en)
|
1999-12-30 |
2007-07-31 |
David Aaron Katz |
Amplification based polymorphism detection
|
|
ATE381626T1
(de)
|
2000-04-13 |
2008-01-15 |
Univ Georgetown |
Genetische diagnose zur feststellung von qt- verlängerungen als unerwünschte reaktion auf arzneimittel
|
|
US6761895B2
(en)
*
|
2000-04-17 |
2004-07-13 |
Yamanouchi Pharmaceutical Co., Ltd. |
Drug delivery system for averting pharmacokinetic drug interaction and method thereof
|
|
US20030054974A1
(en)
|
2001-08-24 |
2003-03-20 |
Aryx Therapeutics |
Non-oxidatively metabolized compounds and compositions, synthetic pathways therefor, and uses thereof
|
|
WO2001096604A2
(en)
*
|
2000-06-12 |
2001-12-20 |
Genicon Sciences Corporation |
Assay for genetic polymorphisms using scattered light detectable labels
|
|
US20020022254A1
(en)
|
2000-07-28 |
2002-02-21 |
Karl Guegler |
Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof
|
|
EP1364334A2
(en)
|
2000-11-30 |
2003-11-26 |
Third Wave Technologies, Inc. |
Systems and method for detection assay production and sale
|
|
GB0102841D0
(en)
|
2001-02-05 |
2001-03-21 |
Novartis Ag |
Organic compounds
|
|
AU2002244568A1
(en)
*
|
2001-03-14 |
2002-09-24 |
Mcgill University |
Individualization of therapy with antipsychotics
|
|
CA2449752A1
(en)
|
2001-06-05 |
2002-12-12 |
Genaissance Pharmaceuticals, Inc. |
Method of identifying a polymorphism in cyp2d6
|
|
WO2004009760A2
(en)
|
2002-07-18 |
2004-01-29 |
Bioventures, Inc. |
Cytochrome p450 genetic variations
|
|
US7195877B2
(en)
*
|
2001-07-20 |
2007-03-27 |
Bioventures, Inc. |
Cytochrome P450 genetic variations
|
|
EP1281755A3
(en)
*
|
2001-07-31 |
2003-06-18 |
Pfizer Products Inc. |
Variants of the human cyp2d6 gene
|
|
DK1425272T3
(da)
|
2001-08-31 |
2011-11-21 |
Novartis Ag |
Optiske isomerer af en iloperidon-metabolit
|
|
ES2436439T3
(es)
*
|
2001-10-30 |
2014-01-02 |
Novartis Ag |
Formulaciones de medicamento de liberación lenta de iloperidona con un polímero
|
|
CA2464995A1
(en)
|
2001-10-31 |
2003-05-08 |
Novartis Ag |
Methods to treat diabetes and related conditions based on polymorphisms in the tcf1 gene
|
|
SI1458888T1
(sl)
|
2001-12-10 |
2011-07-29 |
Novartis Ag |
Metode zdravljenja psihoze in shizofrenije na osnovi polimorfizmov gena cntf
|
|
US20040096874A1
(en)
*
|
2002-04-11 |
2004-05-20 |
Third Wave Technologies, Inc. |
Characterization of CYP 2D6 genotypes
|
|
US20040091909A1
(en)
*
|
2002-07-05 |
2004-05-13 |
Huang Doug Hui |
High throughput cytochrome P450 genotyping
|
|
GB0216416D0
(en)
|
2002-07-15 |
2002-08-21 |
Novartis Ag |
Organic compounds
|
|
ES2557885T3
(es)
|
2003-02-20 |
2016-01-29 |
Mayo Foundation For Medical Education And Research |
Métodos para seleccionar medicamentos antidepresivos
|
|
US7135575B2
(en)
|
2003-03-03 |
2006-11-14 |
Array Biopharma, Inc. |
P38 inhibitors and methods of use thereof
|
|
US20050032070A1
(en)
*
|
2003-08-05 |
2005-02-10 |
Sebastian Raimundo |
Polymorphisms in the human gene for CYP2D6 and their use in diagnostic and therapeutic applications
|
|
WO2005108997A1
(en)
*
|
2004-05-11 |
2005-11-17 |
Bayer Healthcare Ag |
Diagnostics and therapeutics for diseases associated with dipeptidyl-peptidase 6 (dpp6)
|
|
US20100063093A1
(en)
*
|
2007-03-28 |
2010-03-11 |
Curt Wolfgang |
Methods for the administration of iloperidone
|
|
EP1799865B1
(en)
|
2004-09-30 |
2012-06-06 |
Vanda Pharmaceuticals Inc. |
Methods for the administration of iloperidone
|
|
US9074254B2
(en)
|
2007-03-29 |
2015-07-07 |
Vanda Pharmaceuticals, Inc. |
Method of predicting a predisposition to QT prolongation
|
|
US20150259747A1
(en)
|
2007-03-29 |
2015-09-17 |
Vanda Pharmaceuticals Inc. |
Method of predicting a predisposition to qt prolongation
|
|
ES2569480T3
(es)
|
2007-05-18 |
2016-05-11 |
Vanda Pharmaceuticals Inc. |
Marcadores genéticos de eficacia de iloperidona en el tratamiento de síntomas psicóticos
|
|
EP2198048A2
(en)
|
2007-09-10 |
2010-06-23 |
Vanda Pharmaceuticals Inc. |
Prediction of qt prolongation based on snp genotype
|
|
CA2699786C
(en)
|
2007-09-10 |
2019-08-13 |
Vanda Pharmaceuticals, Inc. |
Antipsychotic treatment based on snp genotype
|
|
WO2010117941A1
(en)
|
2009-04-06 |
2010-10-14 |
Vanda Pharmaceuticals, Inc. |
Method of predicting a predisposition to qt prolongation based on abcc2 gene sequence or product thereof
|
|
US8999638B2
(en)
|
2009-04-06 |
2015-04-07 |
Vanda Pharmaceuticals, Inc. |
Method of treatment based on polymorphisms of the KCNQ1 gene
|
|
WO2010117937A1
(en)
|
2009-04-06 |
2010-10-14 |
Vanda Pharmaceuticals, Inc. |
Method of predicting a predisposition to qt prolongation
|
|
WO2010117943A1
(en)
|
2009-04-06 |
2010-10-14 |
Vanda Pharmaceuticals, Inc. |
Method of predicting a predisposition to qt prolongation based on bai3 gene sequence or product thereof
|
|
JP2012526562A
(ja)
|
2009-05-15 |
2012-11-01 |
ヴァンダ ファーマシューティカルズ インコーポレイテッド |
Ｄｒｄ２又はａｎｋｋ１のｓｎｐ遺伝子型に基づく抗精神病治療
|
|
CN108938632A
(zh)
|
2012-03-14 |
2018-12-07 |
万达制药公司 |
用于治疗精神疾病的伊潘立酮代谢物及其应用
|
|
US11071728B2
(en)
|
2015-12-11 |
2021-07-27 |
Vanda Pharmaceuticals Inc. |
Treatment of schizophrenia
|
|
US11214827B2
(en)
|
2018-08-30 |
2022-01-04 |
Vanda Pharmaceuticals Inc. |
Genetic markers for enhancing efficacy of antipsychotic treatment with iloperidone
|
|
US11607408B2
(en)
|
2019-10-15 |
2023-03-21 |
Vanda Pharmaceuticals Inc. |
Method of treatment of schizophrenia
|